Sensus Healthcare (SRTS) vs. The Competition Head to Head Survey

Sensus Healthcare (NASDAQ: SRTS) is one of 113 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it contrast to its competitors? We will compare Sensus Healthcare to similar companies based on the strength of its earnings, profitability, institutional ownership, analyst recommendations, dividends, valuation and risk.

Volatility and Risk

Sensus Healthcare has a beta of -1.29, suggesting that its share price is 229% less volatile than the S&P 500. Comparatively, Sensus Healthcare’s competitors have a beta of 0.81, suggesting that their average share price is 19% less volatile than the S&P 500.

Institutional and Insider Ownership

7.3% of Sensus Healthcare shares are held by institutional investors. Comparatively, 49.0% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 41.1% of Sensus Healthcare shares are held by insiders. Comparatively, 15.8% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Sensus Healthcare and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sensus Healthcare -13.07% -26.74% -15.70%
Sensus Healthcare Competitors -38.83% -90.96% -18.39%

Analyst Recommendations

This is a breakdown of recent ratings for Sensus Healthcare and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sensus Healthcare 0 1 4 0 2.80
Sensus Healthcare Competitors 642 2362 4483 212 2.55

Sensus Healthcare currently has a consensus price target of $12.25, indicating a potential upside of 86.74%. As a group, “Surgical & medical instruments” companies have a potential upside of 368.07%. Given Sensus Healthcare’s competitors higher possible upside, analysts clearly believe Sensus Healthcare has less favorable growth aspects than its competitors.

Valuation and Earnings

This table compares Sensus Healthcare and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Sensus Healthcare $20.59 million -$3.71 million -23.43
Sensus Healthcare Competitors $1.44 billion $104.34 million -175.28

Sensus Healthcare’s competitors have higher revenue and earnings than Sensus Healthcare. Sensus Healthcare is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Sensus Healthcare beats its competitors on 7 of the 13 factors compared.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc. manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides Sentinel service program, which offers its customers protection for their SRT-100 and SRT-100 Vision systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was founded in 2010 and is headquartered in Boca Raton, Florida.

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply